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OBJECTIVES: To estimate the value of survival gains in myelodysplastic syndromes 
(MDS) attributable to the introduction of azacitidine (2004), lenalidomide (2005), 
and decitabine (2006). METHODS: Using multivariate Cox proportional hazards 
models we estimated the increase in survival associated with the introduction 
of new therapies for MDS patients diagnosed from 2001–2011 in the Surveillance, 
Epidemiology, and End Results program registries. The key variable in the haz-
ard model was the post-2006 indicator, which captured the increase in survival 
associated with the introduction of the 3 therapies relative to years 2001–2003. 
Importantly, we included flexible specifications of time trends to capture secular 
changes in survival over the study period. We estimated the cost and utiliza-
tion of the 3 therapies from 2006–2012 using the Optum Touchstone commercial 
claims database. RESULTS: For 38,085 MDS patients diagnosed in 2001 or later 
we estimated that the introduction of these 3 therapies was associated with a 
hazard ratio of 0.901 (p< 0.10). Approximately 25% of MDS patients used at least 
1 of the 3 treatments over this period, implying an increase in median survival 
from 33 to 57.5 months, conditional on treatment observed in the community. 
Using an existing economic model to value survival gains, we estimated that 
the annual value of survival gains associated with the new therapies—i.e., the 
amount patients would be willing to pay for the improved survival profile—
equaled $208,000 per year. Based on this, we estimate the net present value 
of the therapies to all future patients at $101.5 billion. Net of treatment costs, 
85% of the total value accrues to patients. CONCLUSIONS: This study meas-
ured the value of survival gains attributable to 3 novel therapies for MDS and 
found significant benefits. For current and future MDS patients, these thera-
pies will generate $101.5B in value from survival gains, with 85% accruing to 
patients.
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ENROllEd iN mEdiCAid PROgRAm
Khanna R., Joshi N., Pace P., Banahan III B.
University of Mississippi, University, MS, USA
OBJECTIVES: Comprehensive Medicaid population based studies of adherence 
and persistence to tamoxifen and aromatase inhibitors (AIs) including anastro-
zole, exemestane, and letrozole among women with breast cancer are currently 
lacking. The purpose of this study was to estimate the adherence and persistence 
to tamoxifen and AIs among women with breast cancer enrolled across 38 state 
Medicaid programs. Factors predicting adherence and persistence to tamoxifen 
and AIs were also determined. METHODS: Study population included women aged 
18-64 years who were continuously enrolled for a period of three years (2006-2008) 
in Medicaid managed care program across 38 states. Incident users of tamoxifen 
and AIs in 2007 were identified. To assess adherence (proportions of days covered) 
and persistence (gap between prescription refills) to tamoxifen and/or AIs among 
the final sample of women recipients with breast cancer, prescription drug claims 
from index date to 12-month post index date were studied. Logistic regression was 
used to identify predictors of adherence and persistence, respectively. RESULTS: 
Roughly 56% of women with breast cancer were adherent with tamoxifen 
and/or AIs therapy. Higher age, white race (versus black), geographic location in 
Northeast region (versus South, Midwest, and West region), stage II or III/IV (ver-
sus stage 0), and higher number of outpatient visits were associated with higher 
adherence in the regression model. More than three-fourths (~77%) of women 
with breast cancer were persistent with tamoxifen and/or AIs therapy. Regression 
analysis revealed that women with breast cancer residing in Northeast region 
(versus South and West region) and with stage I or III/IV cancer (versus stage 0) 
were more likely to be persistent with therapy. CONCLUSIONS: Adherence and 
persistent to tamoxifen and AIs was less than optimal among women with breast 
cancer enrolled in Medicaid programs. Policy makers should consider implement-
ing interventions aimed at increasing treatment adherence and persistence among 
this population.
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OBJECTIVES: Lenalidomide is a disease-modifying oral medication approved 
for the treatment of multiple myeloma as well as other myelodysplastic syn-
dromes. A CarePak® is a drug regimen packaging tool that simplifies complex 
drug regimens for patients. This tool is frequently used for patients receiving 
drug regimens containing lenalidomide. The impact of this tool on duration of 
therapy has previously not been studied. METHODS: This study was a retro-
spective review of pharmacy claims data. Eligible patients included those who 
filled a lenalidomide prescription more than once, did not have a gap between 
fills longer than 60 days. Patients receiving a CarePak® must have received one 
with all of their dispenses and for at least 6 consecutive months. Duration of 
therapy was calculated as the time between a patient’s first and last fill, includ-
ing the most recent day’s supply. RESULTS: A random sample of patients filling 
between 2009 and 2014 was used for this analysis. To assess differences in dura-
tion of therapy, 225 patients receiving CarePaks® and 225 patients not receiving 
CarePaks® were identified. Duration of therapy for patients utilizing CarePaks® 
and for patients not utilizing CarePaks® was10.5 months and 8.4 months respec-
tively, representing a difference of 2.1 months (p = 0.001). CONCLUSIONS: The 
use of CarePaks® significantly improved duration of therapy in patients receiving 
lenalidomide compared to patients not using CarePaks®. The result of this analysis 
suggests a need for further investigation into the impact of CarePaks® on patient 
outcomes.
ducted on the MedAssets health system data for inpatient and outpatient visits 
diagnosed with MCL for the January 2009 to December 2014 timeframe. Age and 
gender, clinical comorbidities and measures of utilization including number of 
visits and length of stay (LOS) were described. Multivariable regression was used to 
identify significant drivers of hospital-based utilization. RESULTS: The MCL popula-
tion consisted primarily of males (70.8%) and had a mean age of 66 years. Of 35,762 
visits 84.6% occurred in the outpatient setting. Infection (OR= 7.4, p< .0001), fluid and 
electrolyte disorders (OR= 6.3, p< .0001), plegia (OR= 5.9, p< .01), myelosuppression 
(OR= 5.2, p< .0001) and nutritional deficiencies (OR= 3.3, p< .0001) were associated 
with inpatient admissions. The most common complications of treatment included 
myelosuppression (21.7%), gastrointestinal issues (GI, 7.3%), infection (4.9%) and 
renal deficiency (4.8%). Pharmacy (49.2%), room and board (12.8%), laboratory testing 
(10.2%), diagnostic services (7.8%), and surgery (5.8%) costs were the most common 
in this population. When patients were admitted the average LOS was 8.3 days with 
an average cost of $18,291 and 5.0% in-hospital mortality rate. During inpatient hos-
pitalizations 55.0% received chemotherapy, 26.1% had a blood transfusion, 5.2% had 
a bone marrow biopsy, 4.4% had a stem cell transplant, 2.3% had hemodialysis and 
1.5% had radiotherapy. Nutritional deficiencies (IRR= 1.55, p< .0001), plegia (IRR= 1.51, 
p< .0001), infection (IRR= 1.46, p< .0001), myelosuppression (IRR= 1.34, p< .0001) and GI 
(IRR= 1.3, p< .0001) were associated with longer LOS. Readmissions occurred within 
30 days for 28.6% of inpatient admissions with 41.4% of readmissions having main-
tenance chemotherapy or radiotherapy as the primary diagnosis. CONCLUSIONS: 
MCL patients primarily use outpatient services. Inpatient services are required to 
treat complications of treatment such as myelosuppression and infections as well 
as to provide follow-up treatments and care.
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OBJECTIVES: The objective of this analysis was to describe hospital-based resource 
utilization among a population of patients with polycemia vera (PCV). METHODS: 
A retrospective cohort analysis was conducted on a cross-section of patients using 
hospital-based inpatient (N= 7974) and outpatient (N= 47078) services between 2013 
and 2014 with a diagnosis of PCV. Multivariate logistic regression was used to evalu-
ate risk factors for readmission controlling for patient and hospital characteristics 
as well as patient comorbidities. RESULTS: The mean age for PCV patients was 64.4 
years with 58.5% male. Utilization was highest in the OP setting (85.5%) with 68.3% of 
OP visits having a primary diagnosis of PCV. The primary diagnosis for IP admissions 
varied with the most common including infectious and parasitic diseases (6.6%), 
cerebrovascular disease (6.2%), chronic obstructive pulmonary disease (5.5%), heart 
failure (5.2%) and ischemic heart disease (5.2%). PCV patients were primarily treated 
in large (68.4%) and teaching (60.3%) hospitals. The mean Charlson comorbidity 
score was 1.6 with chronic pulmonary disease (18.4%), diabetes (16.7%), congestive 
heart failure (10.3%), cardiovascular disease (10.0%) and renal disease (10.0%) as the 
most common comorbidities. Readmissions occurred within 30 days for 9.0% of IP 
visits for a variety of diagnoses including rehabilitation services (10.9%), chest pain/
shortness of breath (6.8%), infectious and parasitic diseases (4.9%), cerebrovascu-
lar disease (4.1%) and respiratory failure (3.9%). Chronic pulmonary disease (OR = 
1.25, p< .05), hemiplegia or paraplegia (OR = 1.73, p< .05), renal disease (OR = 1.51, 
p< .001) and abdominal drainage procedures (OR = 2.60, p< .01) were associated with 
increased occurrence of readmission. CONCLUSIONS: PCV is primarily managed 
in the community or OP setting. As PCV-related complications develop patients are 
admitted for IP services. These patients are frequently readmitted within 30 days.
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OBJECTIVES: To estimate the economic impact in the treatment of Colombian 
patients with Non-Hodgkin lymphoma developing a time and motion study for the 
IV administration versus subcutaneous (SC) presentation of rituximab. METHODS: 
Time and motion study, observational, multicentric (two private hospitals, one pub-
lic hospital), non-interventional describing costs and times from the admission of 
the patient until their discharge, recording healthcare professionals (HPC), drugs, 
consumables and procedures room. Population evaluated were patients in first 
chemotherapy with rituximab IV with diffuse large B-cell lymphoma and follicu-
lar lymphoma, in regular cycles and in maintenance phase. Finally, we calculated 
the time and cost differences of the treatment of patients with SC (drug still non 
approved in Colombia, therefore these data was obtained from Rule et al., 2014) 
instead IV rituximab from the perspective of the provider. RESULTS: Patients were 
treated with rituximab IV at doses between 520 mg and 700 mg. If they had been 
treated with SC, it estimated to cause net savings of $360 USD per patient, which 
were represented in costs of healthcare professionals (HPC), drugs, consumables 
and procedures room and around 207 minutes of total time expenditure. The cost 
of rituximab SC is the most important savings factor to the provider because it is 
administrated at constant doses non-weight depended. CONCLUSIONS: Rituximab 
SC was a cost-saving strategy for the providers compared with Rituximab IV. As 
results of the savings in cost of treatment, consumables, procedures room and total 
time expenditure, the actual resources of the health provider could be optimized.
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p= 0.047, respectively). The treatment responses and AE were significant factors in 
reducing utility values. The ratios of expected utility to disutility (= 1-utility) in PR, 
SD and PD were 0.47, 0.38, and 0.13 times lower than those of CR, respectively. The 
ratios in AEs(neutropenia, mucositis, thrombocytopenia, and anemia) were 0.45, 
0.51, 0.46, and 0.51 times lower than those of CR, respectively. CONCLUSIONS: This 
study found that patients’ quality of life was significantly deteriorated by relapsed/
refractory non-Hodgkin lymphoma. It is important to provide an appropriate treat-
ment to improve quality of life.
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multiPlE myElOmA
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OBJECTIVES: To map patient-reported EORTC QLQ-C30 scores from the ASPIRE trial 
to EQ-5D utility index scores after identifying mapping algorithms from published 
literature. ASPIRE is a randomized, open-label, phase 3 trial, which evaluated the 
safety and efficacy of carfilzomib with lenalidomide and weekly dexamethasone 
compared with lenalidomide and weekly dexamethasone in patients with relapsed 
multiple myeloma. METHODS: We searched Medline, Embase, NHSEED, CENTRAL, 
DARE (January 2008 through September 2014) and conference proceedings (2010 to 
2014) with the terms, EORTC, QLQ-C30, map, mapping, cross walk, translate, transla-
tion, algorithm, or mapping algorithm. Six articles reported mapping algorithms in a 
cancer population; relevant detailed information was available in four publications 
and extracted. Algorithms were implemented with ASPIRE data using regression 
modeling techniques including ordinary least squares (OLS) at domain and item 
levels, response mapping, and 2-part OLS model at item level where separate regres-
sions were applied for low and high average functional scale domain scores. Utility 
scores at baseline in the ASPIRE trial population were estimated with UK tariffs from 
six algorithms. RESULTS: Mean utility at baseline varied by algorithm and ranged 
from 0.59 (sd = 0.27) (Versteegh 2010, 2-part OLS model) to 0.71 (0.20) (Proskorovsky 
2014; full OLS Model). The range of scores (i.e. min, max) produced from the algo-
rithms varied considerably; as narrow as 0.06 to 1.05 (Proskorovsky 2014; full OLS 
model), and as broad as (-0.43) to 0.98 (Longworth 2014; OLS model). CONCLUSIONS: 
The mapping algorithms yielded stable average estimates and deviations. Selection 
of the better fitting model will involve congruence between modeled estimates and 
the range of utility values estimated for the UK general population (-0.594 to 1.00), 
utility scores reported elsewhere from similar subjects and clinical judgment with 
respect to patient characteristics in the ASPIRE trial.
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(PROS) ANd CliNiCiAN REPORtEd OutCOmES (CROS) iN PAtiENtS With 
mEtAStAtiC bRAiN diSEASE
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OBJECTIVES: To explore the degree of agreement between PRO, time –trade-off (TTO) 
utility and CROs in metastatic brain disease patients- neurocognitive function (NCF), 
Karnofsky performance status (KPS) and quality of life METHODS: We retrospec-
tively analyzed secondary data from 96 brain disease patients (57 randomized and 
39 non-randomized metastatic ) who completed tests to determine TTO utility 
with three time horizons (1, 5, and 10 years), NCF, KPS, quality of life (Functional 
Assessment of Cancer Therapy–Brain [FACT-BR]) and symptoms (MD Anderson 
Symptom Inventory–Brain Tumor [MDASI-BT]). Multiple linear regression analyses 
were used to explore the relationships between TTO utility and other outcome varia-
bles. RESULTS: The CROs significantly associated with TTO utility were the FACT-BR 
(p-value< 0.01 for 10- and 5- year TTO utility and 0.021 for 1-year TTO utility respec-
tively) and the MDASI-BT (sleep) scores (p-value = 0.045 and 0.034 for 10- and 5- year 
TTO utility respectively). However the associations found were not strong. The NCF 
and KPS scores were not significantly associated with TTO utility. CONCLUSIONS: 
None of the functional scores used in metastatic brain disease explain patients’ 
decisions to trade time for better quality of life. Quality of life scores are significant 
predictors of TTO utility, but they have only a limited impact on patients’ decisions. 
Therefore it is essential to use PROs t and incorporate patients’ perspectives of their 
symptoms and care and to complement the traditional CROs.
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uSiNg fACt dAtA tO PREdiCt PREfERENCE-bASEd utility mEASuRES fOR 
PEOPlE With mAligNANt mElANOmA: A REviEW Of thE EvidENCE
Ara R.1, Paisley S.1, Robinson A.A.1, Azough A.2, Mensah L.2
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OBJECTIVES: To identify a published statistical relationship suitable for pre-
dicting UK specific preference-based utility scores (EQ-5D, SF6D or HUI) from 
FACT data (FACT-BRM, FACT-G or FACT-M) in individuals with malignant mela-
noma. METHODS: A range of health and social science databases were searched 
using a keyword strategy with terms relating to the population (people with malig-
nant melanoma) and both the relevant FACT instruments (FACT-G, FACT-M, FACT-
BRM) and the generic preference-based instruments (e.g. EQ-5D, SF-6D, HUI3). 
In addition to the keyword searches, speculative searches using internet search 
engines and citation searching and reference list checking were undertaken with 
no restriction by date, language or study design. Any study which provided a 
statistical regression model describing the relationship between one (or more) 
of the stated FACT and preference-based measures in patients with malignant 
melanoma were included in the review. Identified studies were appraised using a 
checklist for the reporting standards of statistical regression models. RESULTS: 
A total of 19 studies were identified from the literature searches, increasing to 27 
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OBJECTIVES: With oral antineoplastic agents (OAAs) becoming the mainstay of 
treatment for several cancer types, understanding risk factors for medication 
non-adherence is becoming increasingly important in oncology. Patient-reported 
outcome (PRO) instruments may provide valuable insight on barriers to medica-
tion adherence in the real world. This study sought to identify and describe key 
patient-reported risk factors for non-adherence measured in observational stud-
ies evaluating adherence with OAAs. METHODS: A targeted literature review was 
conducted to identify OAA adherence studies utilizing PROs and published between 
January 2004 and December 2014. Key data abstracted from each retained article 
included study design, cancer type, and all PRO instruments or study-specific ques-
tionnaires used. Domains measured by each PRO instrument and questionnaire 
were recorded to understand patient-reported risk factors measured. RESULTS: 
Of 100 articles reviewed, 11 studies met all study inclusion/exclusion criteria. Nine 
studies (82%) used at least one validated PRO instrument and 7 studies (64%) used at 
least one study-specific questionnaire to measure patient-reported risk factors for 
non-adherence. The most commonly used PRO instruments were the Beliefs about 
Medicines Questionnaire (BMQ; n= 4) and the Satisfaction with Information about 
Medicines Scale (SIMS; n= 3). Six studies (55%) used a validated PRO to measure 
health-related quality of life (HRQL); however, only the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 
was used in more than one study. Overall, the most common domains measured by 
PRO instruments or questionnaires were knowledge about medication (n= 7), beliefs 
about medication (n= 6), HRQL (n= 6), attitude toward disease (n= 4), symptoms (n= 3), 
and side effects (n= 3). CONCLUSIONS: Risk factors for non-adherence are com-
monly measured by patient-report in observational studies evaluating adherence 
with OAAs. Further work is needed to clarify advantages and disadvantages of 
using specific PROs to measure relevant risk factors and determine if risk factors 
vary by cancer type.
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mEASuREmENt Of hEAlth StAtE utilitiES fOR RElAPSEd OR REfRACtORy 
PERiPhERAl t-CEll lymPhOmA by uSiNg timE tRAdE-Off ANd viSuAl 
ANAlOg SCAlE mEthOd
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OBJECTIVES: To elicit health utilities for refractory or relapsed peripheral T-cell 
lymphoma (PTCL) using visual analog scaling (VAS) and time trade-off (TTO) meth-
ods, to examine the impact of age on TTO values, and to estimate power curves to 
convert VAS scores to TTO values. METHODS: Health state vignettes for four health 
states (complete remission, partial response, stable disease and progressive disease) 
and four treatment-related adverse events (mucositis, thrombocytopenia, anemia, 
neutropenia) were developed. Utility elicitation from 125 Koreans from the general 
public living in Seoul was conducted using VAS and TTO methods. Linear mixed 
regression and generalized linear mixed models were used to assess the impact 
of age on TTO values. Nonlinear regression was used to estimate power curves to 
convert VAS scores to TTO values. RESULTS: Complete remission was the most pre-
ferred health state (mean TTO value: 0.885), followed by partial response, 0.784; sta-
ble disease, 0.746; and progressive disease, 0.567. Treatment related adverse events 
were related to significant negative impacts. The smallest disutility was associated 
with mucositis (mean TTO disutility: -0.075). The largest disutility was related to 
neutropenia (mean TTO disutility: -0.107). Age was not a significant determinant 
of utility values. Health state (p-value < 0.001) and cancer experience (p-value = 
0.025) had a significant impact on preferences. Two power functions ( , were derived, 
where u = aggregated TTO values and v = aggregated VAS score. CONCLUSIONS: 
This study demonstrated that utility values and power curves for PTCL can be used 
in economic evaluations and decision making.
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utilitiES fOR hEAlth StAtES iN PAtiENtS With RElAPSEd/REfRACtORy 
NON-hOdgkiN lymPhOmA ANd fACtORS iNfluENdiNg utility vAluES
Choi I., Park S., Song J., Jun J.H., Suh D.
Chung-Ang University, Seoul, South Korea
OBJECTIVES: To elicit utility values for health states associated with relapsed/refrac-
tory non-Hodgkin lymphoma and compare utilities after adjusting for demographic 
and societal characteristics in South Korea’s general public. METHODS: Health state 
‘vignettes’ associated with a treatment for R/R non-Hodgkin lymphoma were devel-
oped and characterized as: complete response(CR), partial response(PR), stable(SD), 
progressive disease(PD), and treatment related adverse events(neutropenia, mucosi-
tis, thrombocytopenia, anemia; AE). Vignettes were valued by South Koreans 
using the time trade-off method. The health state vignettes combined informa-
tion gathered from sources such as published literature, consultations with clini-
cal specialists, and interviews with patients, which were used to develop health 
dimensions consistent with the EQ-5D. Utility values were summarized and com-
pared by characteristics of interviewees. The influencing factors of utility values 
were estimated using mixed Beta regressions. Since the utility values for various 
health states were measured by a subject, subjects were used as a strata. The glim-
mix SAS procedure was used to determine factors influencing utility. RESULTS: 
A total 166 Korean were interviewed. The subjects were aged 46(±10.6) years old 
with a near even gender split. Mean utilities were CR;0.89(±0.08), PR;0.79(±0.13), 
SD;0.75(±0.12), PD;0.45(±0.16), AE-neutropenia;0.70(±0.17), AE-mucositis;0.79(±014), 
AE-thrombocytopenia;0.77(±0.14), and AE-anemia;0.79(±0.13). Utility values for 
PR and PD were significantly different between males and females (p= 0.0135 and 
